Avantor Investor Day Presentation Deck

Proven to execute and perform Innovation Shanghai New European biorepository center M&A Ritter acquisition Rim Bio acquisition Largest U.S. Healthcare IPO Stated goal: Navantor™ What we achieved¹: NYSE listed innovation center REVENUE GROWTH 4-6% organic growth ~7% organic growth SUSTAINABILITY UNSDGS alignment Inaugural report S ADJ. EBITDA MARGIN 50-100 bps expansion per year ~110 bps per year ADJ. EPS GROWTH Mid-Teens+ TAX RATE Low 30's ADJ. NET LEVERAGE 2-4X by 2021 ~55% -24% 3.2X² growth leverage effective tax rate 1. Based on FY18 actual to FY21 estimates as per Q2 earnings call guidance, excluding pending M&A 2. 2021 YE estimate as per Q2 earnings call guidance, excluding pending M&A CREDIT UPGRADES Single use expansions Europe Asia Moody's S&P Fitch North America 13

View entire presentation